Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Pfizer is planning to advance a daily weight loss pill to mid-stage trials this year in hopes that the experimental drug will help the company break into a market projected to be worth more than $100bn a year.
The pharmaceutical group said on Thursday that it had selected a once-daily oral medicine to test in phase-two studies in the second half of this year.
The compound used in the Pfizer product is similar to that used in the already-approved weight loss injections Wegovy and Zepbound, produced by Novo Nordisk and Eli Lilly.
Those two companies are already testing weight loss pills in phase-three trials.
This is a developing story